The global protein drugs market was valued $xx Mn. in 2019 and is expected to reach $xx Mn in 2027, at a CAGR of xx%.
Market Introduction and Overview
Protein drugs are artificially synthesized proteins for treatment of chronic diseases such as cancer and diabetes. They are fast-acting medicines capable of delivering small protein molecules to the body in specific amount. Protein drugs has become an important segment of the healthcare industry and has a high demand. Advances in biological sciences have shown a positive impact on the global protein drugs market. The future of this market is expected to be promising due to rise in prevalence of chronic diseases, unmet needs for effective treatments and advances in drug development and manufacturing.
Advantages of protein drugs such as their efficiency, efficacy and low toxicity are boosting the market growth. Factors such as rising R&D activities, increasing pharmaceutical industries, rapid advances in genetic engineering are the key drivers to the market. Increasing adoption of protein drugs in emerging economies is expected to grow opportunities for the market in future.
However, high costs of drugs due to expensive procedures and complex approval processes are restraining the market growth.
The report covers the detailed analysis of global market for protein drugs with the classifications of the market based on products, applications and region. Analysis of past market dynamics from 2016 to 2019 is given in the report, which will help readers to benchmark the past trends with current market scenarios with the key players contribution in it.
The report has profiled seventeen key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analysing the market and estimation the size of the same. The growing healthcare infrastructure in each region is different and focus is given on availability of advanced technology and new techniques. Report has come up with recommendations for future hot spot in APAC region. New research findings, funding policies for projects and its impact on global protein drugs market are covered in the report.
Segment Analysis
The monoclonal antibodies segment is expected to grow at a CAGR of 14.4% in the forecast period owing to the rising prevalence of cancer cases. Increasing research collaborations for development of strong drug pipelines is a major factor driving the market growth. The success of mAbs such as Avastin, Herceptin and Rituxan earned a revenue of $xx, $xx and $xx Mn in 2019. The success of these antibodies increased the interest of manufacturers to invest in the segment. In March 2019, FDA approved Trazimera for the treatment of metastatic gastric adenocarcinoma and HER2 breast cancer, thereby fuelling the market growth.
In July 2020, UCB announced a licensed agreement with Roche and Genentech for the development of UCB0107, a monoclonal antibody potential for treating patients with Supranuclear palsy (PSP) and Alzheimer’s. An increasing number of government initiatives and funding for clinical trials of drugs, which can be used in the treatment of COVID-19 are expected to favour the segment growth.
Global Protein Drugs Market
Market Segmentation
The Global protein Drugs Market is segmented based on-
Products
• Monoclonal Antibodies
• Insulin
• Fusion Protein
• Erythropoietin
• Interferon
Applications
• Metabolic Disorders
• Immunologic Disorders
• Haematological Disorders
• Cancer
• Genetic Disorders
• Hormonal Disorders
Regional Insights
Global Protein Drugs Market1
North America generated a revenue of $xx Mn in 2019 and is expected to emerge as a dominant region in the forecast period. Increasing prevalence cancer cases, growing research activities, advanced treatment techniques, favourable reimbursement policies, development of novel products are the multiple factors boosting the growth of market in this region
Asia Pacific is expected to witness growth in the forecast period. Owing to the increasing population and rising diabetic cases, growing healthcare facilities in developing nations and advanced treatment options, the market in this region is anticipated to grow.
Key players operating the Global Protein Drugs Market
• Abbott Laboratories
• AstraZeneca
• Amgen Inc
• Baxter International Inc
• Eli Lilly and Company
• F.Hoffmann-La Roche Ltd
• Johnson & Johnson
• Merck & Co, Inc
• Novo Nordisk A/S
• Pfizer Inc
• Sanofi
• UCB Group
• Genentech Inc
• Teva Pharmaceuticals
• Biogen Inc
• Novartis
• Generex Biotechnology
For More Information Visit @: Maximize Market Research Company
This Report Is Submitted By : Maximize Market Research Company
Customization of the report:
Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.
About Maximize Market Research:
Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.
